secwatch.observer — SEC 8-K summary
======================================

Issuer:     Molecular Templates, Inc. (—)
CIK:        0001183765
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001171843-24-001712
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Molecular Templates reports Q4 2023 net loss $3.9M; BMS termination, $9.5M placement
--------------------------------------------------------------------------------

- Q4 2023 net loss $3.9M ($0.73/sh) vs $22.0M ($5.87/sh) in Q4 2022; revenue $7.0M vs $2.6M.
- Cash $11.5M as of Dec 31, 2023; $9.5M private placement closing extends runway to Q4 2024.
- Bristol-Myers Squibb terminates collaboration effective June 13, 2024; MTEM plans cost reductions.
- MT-6402 shows confirmed PR (70% reduction) in HNSCC; dose expansion enrolling low PD-L1+ patients.
- MT-8421 dose escalation second cohort enrolling; early evidence of Treg depletion and T-cell activation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/0001171843-24-001712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/f8k_032924.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer